Medicamen Biotec

{
  "main_header": {
    "sid": 770569,
    "name": "Medicamen Biotec",
    "stock_name": "Medicamen Biotec",
    "full_name": "Medicamen Biotech Ltd",
    "name_url": "stocks-analysis/medicamen-biotec",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "365.15",
    "chg": 6.8,
    "chgp": "1.9%",
    "dir": 1,
    "prev_price": "358.35",
    "mcapval": "495.25 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531146,
    "symbol": "MEDICAMEQ",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE646B01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "18.01 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-biotec-770569-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Medicamen Biotech Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-valuation-shifts-signal-price-attractiveness-challenges-3817105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MedicamenBiotec_valuationdot_3817105.png",
        "date": "2026-02-03 08:01:07",
        "description": "Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, raises questions about the stock's price attractiveness relative to its historical averages and peer group. Despite a recent uptick in share price, the company’s fundamental scores and returns suggest a cautious approach for investors."
      },
      {
        "title": "Medicamen Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-3803123",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_mojoScore_3803123.png",
        "date": "2026-01-24 10:10:03",
        "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mild Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-shows-mixed-technical-signals-amid-mild-momentum-shift-3800998",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_technicaldot_3800998.png",
        "date": "2026-01-23 08:01:23",
        "description": "Medicamen Biotech Ltd has experienced a nuanced shift in its technical momentum, with several key indicators signalling a transition from bearish to mildly bearish territory. Despite a recent uptick in price, the stock continues to face headwinds amid mixed signals from MACD, RSI, moving averages, and other technical tools, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mildly Bearish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-shows-mixed-technical-signals-amid-mildly-bearish-momentum-3786347",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_technicaldot_3786347.png",
        "date": "2026-01-09 08:06:19",
        "description": "Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026."
      },
      {
        "title": "Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-shows-mixed-technical-signals-amid-price-momentum-shift-3785105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_technicaldot_3785105.png",
        "date": "2026-01-08 08:15:00",
        "description": "Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Medicamen Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-3778876",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_mojoScore_3778876.png",
        "date": "2026-01-02 10:10:03",
        "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotec-upgraded-from-strong-sell-to-sell-by-marketsmojo-3765666",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicamenBiotec_mojoScore_3765666.png",
        "date": "2025-12-22 10:10:04",
        "description": "Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory."
      },
      {
        "title": "Why is Medicamen Biotec falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-medicamen-biotec-fallingrising-3757747",
        "imagepath": "",
        "date": "2025-12-13 01:04:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Defy Broader Market Trends</strong></p>\n<p>Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.</p>\n<p>The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ..."
      },
      {
        "title": "Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotec-upgraded-from-strong-sell-to-sell-by-marketsmojo-3738147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicamenBiotec_mojoScore_3738147.png",
        "date": "2025-12-01 10:09:02",
        "description": "Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse."
      }
    ],
    "total": 6209,
    "sid": "770569",
    "stock_news_url": "https://www.marketsmojo.com/news/medicamen-biotech-770569"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "16-Jan-2026",
      "details": "Compliance- Certificate under Reg 74 (5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 (LODR)- EU Approval For Product Registration Of Paracetamol",
      "datetime": "07-Jan-2026",
      "details": "Announcement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Dec-2025",
      "details": "Closure of Trading Window - For declaration of unaudited financial results for the quarter ended on December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Medicamen Biotech Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-02-03 08:01:07

Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, raises questions about the stock's price attractiveness relative to its historical averages and peer group. Despite a recent uptick in share price, the company’s fundamental scores and returns suggest a cautious approach for investors.

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-01-24 10:10:03

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mild Momentum Shift

2026-01-23 08:01:23

Medicamen Biotech Ltd has experienced a nuanced shift in its technical momentum, with several key indicators signalling a transition from bearish to mildly bearish territory. Despite a recent uptick in price, the stock continues to face headwinds amid mixed signals from MACD, RSI, moving averages, and other technical tools, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mildly Bearish Momentum

2026-01-09 08:06:19

Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026.

Read full news article

Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift

2026-01-08 08:15:00

Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-01-02 10:10:03

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-22 10:10:04

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory.

Read full news article

Why is Medicamen Biotec falling/rising?

2025-12-13 01:04:49

Short-Term Gains Defy Broader Market Trends

Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.

The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ...

Read full news article

Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-01 10:09:02

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse.

Read full news article

View All News